AI pathology adoption is gaining momentum as Leeds Teaching Hospitals NHS Trust expands its global reach. The Trust has secured a commercial agreement with Epredia to scale its innovative TANGO technology. This move aims to accelerate AI pathology adoption across international healthcare systems.
TANGO is an imaging innovation created by the National Pathology Imaging Co-operative that enhances the quality of staining done in laboratories. TANGO ensures efficient and effective diagnostic processes. Furthermore, TANGO is helpful in digital pathology and enhances cancer diagnostics using artificial intelligence. TANGO has been validate in global research studies.
Professor David Brettle, Chief Scientific Officer at Leeds Teaching Hospitals NHS Trust, said: “This is a proud moment for Leeds and for the NHS. TANGO was developed to offer a powerful solution in digital pathology to support clinical practice, and this shows how ideas developed on the frontline in the NHS can grow into innovations with global impact. By partnering with Epredia, we now have an opportunity to deploy this technology across the NHS and far wider, helping laboratories to adopt AI-enabled cancer diagnostics and ultimately provide patients with quicker results.”
Expanding Digital Pathology Through Global Healthcare Collaboration
Under the agreement, Epredia will incorporate TANGO into its new line of pathology slide solutions. Hence, laboratories will be able to enjoy the benefits of the technology in making more accurate diagnoses. Furthermore, it is intended that Epredia will utilize its worldwide distribution system.
Steven Lynum, President and CEO at Epredia, said: “We share Leeds Teaching Hospitals’ passion and ambition for driving healthtech innovations and solutions to generate real-world change. Digital pathology and AI have the potential to help accelerate cancer diagnostics speed and quality and ultimately improve patient care. By adding this powerful innovation to our world-class portfolio of precision cancer diagnostics products, we are investing in technologies that can help make that future a reality.”
TANGO-based solutions will be introduced by Epredia, an industry leader in precision diagnostics in cancer, towards the end of 2026. The partnership will improve diagnostic efficiency and accuracy while creating new investment opportunities in UK health technology innovation. TANGO helps in overcoming the inconsistencies in diagnostic staining, which affect AI’s accuracy. As such, it improves the quality control and provides faster diagnoses.
Antony Kildare, Chair of Leeds Teaching Hospitals NHS Trust, added: “This collaboration demonstrates how partnerships between NHS and industry can accelerate healthtech and life sciences innovations to transform healthcare. It’s an exciting step forward for the Trust and builds on Leeds’ reputation as a centre for healthtech excellence by taking home-grown innovation to the global stage. As well as delivering real-world clinical solutions, the agreement offers strong returns and brings economic benefits by creating healthtech jobs in Leeds and driving investment back to the NHS to fund future research and innovation.”
Tracy Brabin, Mayor of West Yorkshire, said: “As the home of one of Europe’s largest teaching hospitals, a network of over 300 firms and a £160 million investment zone, West Yorkshire is a global magnet for health innovation.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
